Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and the companies entered a three-year research collaboration to discover and develop novel pharmaceuticals to treat obesity and related co-morbidities. Under the agreement, Novo Nordisk receives the full rights to develop and commercialize the lead program, while the Embark shareholders will receive €15 million upfront in cash and are eligible to receive potential development, regulatory, and commercial milestone...